Market Outlook for China’s Medical Robot Industry

I. Definition of Medical Robots

Medical robots are intelligent service robots used in healthcare settings. Integrating artificial intelligence, precision machinery, biomedicine and multimodal sensing technologies, they can assist or replace medical staff in diagnosis, treatment, rehabilitation and nursing.

Their core advantages include high precision and safety, autonomous decision-making and adaptability across multiple scenarios. They can be applied in operating rooms, wards, homes and telemedicine settings. As a key driver of medical technology innovation, medical robots are advancing the development of precision healthcare without boundaries, while also facing challenges in cost, ethics and technological self-reliance.

II. Industry Policies

In recent years, China’s medical robot industry has received strong attention from governments at all levels and key support from national industrial policies. A series of policies, including the Measures to Optimize Full-Life-Cycle Regulation and Support Innovation in High-End Medical Devices (Draft for Comments), the Decision on Further Deepening Reform Comprehensively to Advance Chinese Modernization, and the Guiding Opinions on Implementing the Public Safety Standardization Foundation Project, have provided clear policy guidance and broad market prospects for the industry, creating a favorable operating environment for enterprises.

III. Current Development of the Medical Robot Industry

1. Overall Market

Driven by policy support, rising rehabilitation demand from population aging, and the trend toward more precise surgery, China’s medical robot industry is in a phase of rapid growth. In 2024, China’s medical robot market reached approximately RMB 13.58 billion, with a compound annual growth rate of 22.96% over the past five years. Analysts from the China Business Industry Research Institute forecast that the market will grow to RMB 14.94 billion in 2025.

2. Surgical Robots

As the segment with the highest technical barriers, China’s surgical robot market continues to expand. In 2024, the market size reached approximately RMB 9.59 billion, with a compound annual growth rate of 34.5% over the past five years. It is expected to reach RMB 11.03 billion in 2025.

3. Rehabilitation Robots

Driven by supportive national policies and growing social demand, China’s rehabilitation medical device industry has developed rapidly, and the rehabilitation robot market continues to expand. In 2024, the market size was approximately RMB 1.529 billion. It is expected to reach RMB 1.682 billion in 2025.

4. Investment and Financing

China’s medical robot sector has remained active in investment and financing. According to IT Juzi, from January to April 2025, 19 disclosed investment events were recorded, with disclosed financing totaling approximately RMB 1.752 billion.

5. Corporate Deployment

The medical robot industry is showing rapid growth and technological diversification. Benefiting from rehabilitation demand driven by aging and the trend toward more precise surgery, the market has achieved a compound annual growth rate of over 22%, while domestic penetration in orthopedics and endoscopic surgery has exceeded 30%.

Technological innovation is focused on AI integration, such as preoperative planning and real-time navigation, 5G-enabled remote operation, and high-precision sensing, reducing surgical errors to the sub-millimeter level. Market demand is also expanding to primary healthcare institutions, with rehabilitation robot demand growing by 35%. Under policy support, annual investment and financing has exceeded RMB 2.6 billion, forming a closed-loop ecosystem covering R&D, clinical application and industrialization.

IV. Key Companies in the Medical Robot Industry

1. HGZN

Jiangsu Hagong Intelligent Robot Co., Ltd. is mainly engaged in intelligent manufacturing, with core products including high-end equipment manufacturing and one-stop robot platforms. In the first quarter of 2025, the company reported revenue of RMB 106 million, down 75.23% year on year, and a net loss attributable to shareholders of RMB 28 million. In 2024, high-end equipment manufacturing and the one-stop robot platform accounted for 99.99% and 0.01% of total revenue, respectively.

2. WEGO Orthopaedic

WEGO Orthopaedic is actively building a closed-loop ecosystem integrating orthopedic surgery and rehabilitation. Its core layout focuses on orthopedic surgical robots, including products developed through its joint venture with Maibu Robot, orthopedic rehabilitation robots and supporting orthopedic rehabilitation assessment systems.

Through technological innovation, the company aims to cover the full process from precise preoperative planning and robot-assisted intraoperative diagnosis and treatment to intelligent postoperative rehabilitation. It is also extending application scenarios from hospitals to communities and homes, promoting intelligent transformation in orthopedics while addressing the challenges brought by centralized procurement of traditional consumables.

In the first quarter of 2025, the company reported revenue of RMB 290 million, down 16.67% year on year, and net profit attributable to shareholders of RMB 52 million, up 48.57% year on year. In 2024, its main products included joints, spine, sports medicine and tissue repair, accounting for 29.01%, 28.99% and 19.11% of total revenue, respectively.

3. TINAVI

TINAVI is a pioneer and leader in China’s orthopedic surgical robot sector. Its core “TiRobot” series has been widely applied in spine, joint and trauma surgeries. The company focuses on building a complete ecosystem of equipment, consumables and services, while strengthening collaborative R&D between AI technologies and surgical robots through its subsidiary AISimply.

Its products emphasize “one machine for multiple applications,” and cumulative surgical cases have exceeded 100,000. TINAVI has also built a strong nationwide clinical support network and is actively exploring remote surgery applications, further consolidating its market leadership.

In the first quarter of 2025, the company reported revenue of RMB 59 million, up 103.45% year on year, and a net loss attributable to shareholders of RMB 13 million. In 2024, orthopedic surgical navigation and positioning robots, supporting equipment and consumables, and technical services accounted for 41.54%, 30.67% and 24.02% of total revenue, respectively.

4. MicroPort MedBot

MicroPort MedBot adopts an international, multi-track development strategy, focusing on five “golden tracks”: endoscopic surgery, orthopedics, vascular intervention, natural orifice surgery and percutaneous puncture.

Its representative products include the Toumai endoscopic surgical robot, SkyWalker joint replacement robot, which has initiated FDA registration and is the first domestic product of its kind in the joint surgery field, bronchoscopic surgical robots, already used in clinical scenarios such as COVID-19 diagnosis and treatment, and vascular interventional robots.

The company actively cooperates with international partners, such as France’s Robocath and Singapore’s NDR, to accelerate technology commercialization and global expansion in frontier areas including vascular intervention and percutaneous puncture.

In 2024, the company reported revenue of RMB 257 million, up 144.76% year on year, and a net loss attributable to shareholders of RMB 642 million. Sales of medical devices and accessories accounted for 98.12% of total revenue.

5. Jianjia Robot

Jianjia Medical is a leading domestic surgical robot company. Through a three-line layout covering joints, full orthopedics and dentistry, it has built differentiated competitive advantages.

Its core Arthrobot joint robot breaks the monopoly of imported products with its “three-procedure-in-one” capability. Its YOZX full orthopedic robot covers spine, trauma and joint surgeries, while its THETA dental implant robot fills a domestic gap with an integrated cantilever design.

In 2024, Jianjia accelerated commercialization through multiple product approvals, including YOZX and GAPSENSE, as well as strategic partnerships with companies such as Zhuoxin Medical and Taoying Medical. The company also plans to raise RMB 1.5 billion through a STAR Market IPO to support technology R&D and capacity expansion.

V. Development Prospects

1. Technological Self-Reliance Accelerates Domestic Substitution

Breakthroughs in core technologies such as single-port laparoscopy and snake-arm operation are significantly improving the clinical applicability of high-end medical robots in China.

For example, Shurui Robot’s snake-shaped surgical arm can complete complex procedures through an incision of only 2.5 cm. Its superelastic nickel-titanium alloy rod structure balances high load capacity with precise control and has been applied in more than 40 innovative procedures in urology, gynecology and other fields.

MicroPort MedBot’s SkyWalker joint replacement system has obtained certification in China, the United States and Europe, filling an international gap for China’s high-end surgical robots. These breakthroughs are breaking foreign monopolies and driving the penetration rate of domestic surgical robots from 3.7% in 2020 to 11.2% in 2025, laying the foundation for broader import substitution.

2. Clinical Scenario Expansion Unlocks Diverse Value

Medical robots are increasingly penetrating remote diagnosis and treatment, specialized care and other clinical scenarios, reshaping healthcare service models.

Enabled by 5G, ultra-remote surgery is becoming a reality. For example, Sir Run Run Shaw Hospital affiliated with Zhejiang University operated a MicroPort robot in Shanghai to complete an interprovincial cholecystectomy, helping address regional imbalances in medical resources.

In rehabilitation, exoskeleton robots combined with brain-computer interface technologies are enabling motor function reconstruction for patients with paraplegia. Specialized tool-type robots, such as TINAVI’s orthopedic navigation system, can adapt to multiple departments by replacing end effectors, increasing utilization of a single device by 300%. Scenario innovation is upgrading medical robots from standalone tools to core carriers of smart healthcare systems.

3. Interdisciplinary Integration Creates Next-Generation Technologies

The deep integration of artificial intelligence, biomaterials and other frontier technologies is driving medical robots toward greater intelligence and biological functionality.

The OptoChat AI large model integrates 300,000 pieces of medical data to assist doctors in planning sub-millimeter surgical pathways. The combination of absorbable biomaterials and 3D printing enables implantable nanorobots for targeted tumor therapy. The linkage of brain-computer interfaces and exoskeletons is making mind-controlled rehabilitation training possible.

Such interdisciplinary innovation is not only breaking the physical limits of traditional robotic arms, but also leading medical robots toward a new paradigm of “programmable biological structures,” providing disruptive tools for precision medicine.

VI. Conclusion

Supported by favorable policies, rising market demand and continuous technological innovation, China’s medical robot industry is entering a golden period of rapid development. As technological self-reliance accelerates domestic substitution, clinical applications continue to expand, and interdisciplinary integration gives rise to next-generation technology paradigms, the industry is set to gain broader growth opportunities.

China’s medical robot sector is expected to occupy an important position in the global market and make significant contributions to advancing medical technology and improving healthcare services in China.